Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice

Figures & data

Table 4 Mean (with maximum and minimum range) comparative treatment costs for administering intravenous iron at three dose levels (600 mg, 1000 mg and, 1600 mg)

	Comparative costs, GBP£
	Iron sucrose	Low molecular weight iron dextran	Iron isomaltoside 1000	Ferric carboxymaltose	Blood
600 mg iron
Mean	261.61	221.19	170.21	173.23	449.80
Min	241.61	206.88	163.54	164.94	442.67
Max	281.61	235.49	176.87	181.52	456.92
1000 mg iron
Mean	436.02	253.07	231.71	249.63	737.55
Min	402.68	238.76	225.50	241.34	727.67
Max	469.35	267.37	237.92	257.92	747.42
1600 mg iron
Mean	697.63	300.89	333.41	404.86	1169.17
Min	644.29	286.58	327.20	394.27	1155.17
Max	750.96	315.19	339.62	415.44	1183.17

Table 5 Relative cost position (mean) of iron isomaltoside 1000 and ferric carboxymaltose at three dose levels compared to standard treatments and blood

	Cost difference, GBP£ (±%)
	Iron isomaltoside 1000 vs iron sucrose	Iron isomaltoside 1000 vs low molecular weight iron dextran	Iron isomaltoside 1000 vs blood
600 mg dose	−91.40 (−34.93%)	−50.98 (−23.05%)	−279.59 (−62.16%)
1000 mg dose	−204.31 (−46.86%)	−21.36 (−8.44%)	−505.84 (−68.58%)
1600 mg dose	−364.22 (−52.21%)	+32.52 (+10.81%)	−835.76 (−71.48%)
	Ferric carboxymaltose vs Iron sucrose	Ferric carboxymaltose vs low molecular weight iron dextran	Ferric carboxymaltose vs blood
600 mg dose	−88.38 (−33.78%)	−47.96 (−21.68%)	−276.57 (−61.49%)
1000 mg dose	−186.39 (−42.75%)	−3.44 (−1.36%)	−487.92 (−66.15%)
1600 mg dose	−292.77 (−41.97%)	+103.97 (+34.55%)	−764.31 (−65.37%)

Table 6 Relative cost position (mean) of iron isomaltoside 1000 versus ferric carboxymaltose at three dose levels of iron (600 mg, 1000 mg and, 1600 mg)

	Mean cost iron isomaltoside 1000 (GBP£)	Mean cost ferric carboxymaltose (GBP£)	Mean cost saving iron isomaltoside 1000 vs ferric carboxymaltose (GBP£)
600 mg dose	170.21	173.23	3.02 (1.74%)
1000 mg dose	231.71	249.63	17.92 (7.18%)
1600 mg dose	333.41	404.86	71.45 (17.65%)

Table 1 Comparative intravenous drip infusion regimens^1,2,18,19,27

Product	Iron sucrose	Low molecular weight iron dextran	Iron isomaltoside 1000	Ferric carboxymaltose	Blood
Dose limitation	100 mg or 200 mg	100–200 mg	20 mg/kg body weight to total body weight	20 mg/kg up to max 1000 mg	None
Rate of administration	100 mg in 15 mins	100 mg in 37.5 mins	0–5 mg/kg body weight in 15 mins	100 mg to 200 mg no minimum time quoted	I unit (equ 200 mg iron) 90 mins
	200 mg in 30 mins	200 mg in 41.25 mins	6–10 mg/kg body weight in 30 mins	≥200–500 mg 6 mins
			11–20 mg/kg body weight in 60 mins	≥500–1000 mg 15 mins
Test dose	Required for first administration	Required at each administration	Not required	Not required	N/A

Abbreviations: equ, equivalent; N/A, not applicable.

Table 2 Comparative intravenous injection regimens^1,2,18,19

Product	Iron sucrose	Low molecular weight iron dextran	Iron isomaltoside 1000	Ferric carboxymaltose	Blood
Dose limitation	200 mg	200 mg	200 mg	1000 mg	N/A
Rate of administration	100 mg in 5 mins minimum – 10 mins maximum 200 mg in 10 mins minimum – 20 mins maximum	100 mg in 25 mins 200 mg in 35 mins	2–4 mins	>200–500 mg at 100 mg/min 500–1000 mg over 15 mins	N/A
Test dose	Required for first administration	Required at each administration	Not required	Not required	N/A

Abbreviation: N/A, not applicable.

Table 3 Comparative high dose infusion regimens^1,2,18,19

Product	Iron sucrose	Low molecular weight iron dextran	Iron isomaltoside 1000	Ferric carboxymaltose	Blood
Dose limitation	200 mg	20 mg/kg	20 mg/kg	20 mg/kg max 1000 mg	N/A
Rate of administration	N/A*	20 mg/kg first 25 mg (test dose) over 15 mins then balance over 4 hours	0–10 mg/kg in 30 mins 11–20 mg/kg in 60 mins	≥200–500 mg 6 mins ≥500–1000 mg 15 mins	N/A
Test dose	N/A	Required at each administration	Not required	Not required	N/A

* Note: Requires multiple administrations of 200 mg intravenous injections to deliver total dose.

Abbreviation: N/A, not applicable.

Ferinject [summary of product characteristics]LondonVifor Pharma UK Ltd2011 [updated October 25]. Available at: http://www.medicines.org.uk/EMC/medicine/24167/SPC/Ferinject+(ferric+carboxymaltose)/Accessed November 9, 2011

 Google Scholar

Monofer 100 mg/mL solution for injection/infusion [summary of product characteristics]LondonPharmacosmos UK Ltd2011 [updated March 21]. Available at: http://www.medicines.org.uk/EMC/medicine/23669/SPC/Monofer+100mg+ml+solution+for+injection+infusion/Accessed October 19, 2011

 Google Scholar

Venofer (iron sucrose) [summary of product characteristics]LondonVifor Pharma UK Ltd2011 [updated March 30]. Available at: http://www.medicines.org.uk/EMC/medicine/24168/SPC/Venofer+(iron+sucrose)/Accessed November 9, 2011

 Google Scholar

CosmoFer [summary of product characteristics]LondonPharmacosmos UK Ltd2011 [updated January 27]. Available at: http://www.medicines.org.uk/emc/medicine/14139/SPC/CosmoFer/Accessed October 19, 2011

 Google Scholar

McClellandDBLHandbook of Transfusion Medicine4th edLondonStationary Office2007 Available from: http://www.transfusionguidelines.org.uk/docs/pdfs/htm_edition-4_all-pages.pdfAccessed February 9, 2011

 Google Scholar